Daré Bioscience CEO to Participate in Maxim Group’s Infectious Disease Virtual Conference
April 28 2020 - 8:00AM
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s
health innovation, today announced that Sabrina Martucci Johnson,
President and Chief Executive Officer, will participate in a panel
discussion during the Infectious Disease Virtual Conference
presented by Maxim Group on May 5, 2020. Ms. Johnson will be a
member of the panel discussing non-antibiotic anti-infectives,
scheduled from 10:30 a.m. to 12:00 p.m. Eastern Time.
During the panel discussion, Ms. Johnson will
share insights from the Company’s DARE-BV1 development program.
DARE-BV1, a novel thermosetting bio-adhesive hydrogel formulated
with clindamycin phosphate 2%, is an investigational product for
the treatment of bacterial vaginosis (BV), one of the most common
vaginal infections. The Company plans to initiate a Phase 3 study
of DARE-BV1 during 2020, have topline data available by the end of
the year and submit a new drug application (NDA) for DARE-BV1 with
the FDA during the first half of 2021.
For additional information, please visit
https://m-vest.com/insights/blog/Infectious-Disease-Virtual-Conference-2020.
About Daré Bioscience
Daré Bioscience is a clinical-stage
biopharmaceutical company committed to the advancement of
innovative products for women’s health. The company’s mission is to
identify, develop and bring to market a diverse portfolio of
differentiated therapies that expand treatment options, improve
outcomes and facilitate convenience for women, primarily in the
areas of contraception, vaginal health, sexual health, and
fertility.
Daré’s product portfolio includes potential
first-in-category candidates in clinical development: Ovaprene®, a
hormone-free, monthly contraceptive intravaginal ring whose U.S.
commercial rights are under a license agreement with Bayer;
Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to
treat female sexual arousal disorder utilizing the active
ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of
clindamycin phosphate 2% to treat bacterial vaginosis via a single
application; and DARE-HRT1, a combination bio-identical estradiol
and progesterone intravaginal ring for hormone replacement therapy
following menopause. To learn more about Daré’s full portfolio of
women’s health product candidates, and mission to deliver
differentiated therapies for women, please visit
www.darebioscience.com.
Daré may announce material information about its
finances, product candidates, clinical trials and other matters
using its investor relations website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré will use these channels
to distribute material information about the company, and may also
use social media to communicate important information about the
company, its finances, product candidates, clinical trials and
other matters. The information Daré posts on its investor
relations website or through social media channels may be deemed to
be material information. Daré encourages investors, the media, and
others interested in the company to review the information Daré
posts on its investor relations website
(https://darebioscience.gcs-web.com/) and to follow these Twitter
accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the
list of social media channels the company may use to communicate
information will be posted on the investor relations page of the
company's website mentioned above.
Forward-Looking Statements
Daré cautions you that all statements, other
than statements of historical facts, contained in this press
release, are forward-looking statements. Forward-looking
statements, in some cases, can be identified by terms such as
“believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”
“design,” “intend,” “expect,” “could,” “plan,” “potential,”
“predict,” “seek,” “should,” “would,” “contemplate,” “project,”
“target,” “tend to,” or the negative version of these words and
similar expressions. Such statements include, but are not limited
to, statements relating to Daré’s expectations for the timing of
commencement and announcement of topline results of a Phase 3 study
of DARE-BV1 for the treatment of BV and submission of a NDA for
DARE-BV1, and the potential for regulatory approval to market
DARE-BV1 based on a single successful Phase 3 study.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Daré’s actual
results, performance or achievements to be materially different
from future results, performance or achievements expressed or
implied by the forward-looking statements in this press release,
including, without limitation, risk and uncertainties related to:
the effects of the COVID-19 pandemic on Daré’s operations,
financial results and condition, and ability to achieve current
plans and objectives; Daré’s ability to raise additional capital
when and as needed to advance its product candidates and continue
as a going concern; Daré’s ability to develop, obtain regulatory
approval for, and commercialize its product candidates; the failure
or delay in starting, conducting and completing clinical trials or
obtaining FDA or foreign regulatory approval for Daré’s product
candidates in a timely manner; Daré’s ability to conduct and design
successful clinical trials, to enroll a sufficient number of
patients, to meet established clinical endpoints, to avoid
undesirable side effects and other safety concerns, and to
demonstrate sufficient safety and efficacy of its product
candidates; the risk that positive findings in early clinical
and/or nonclinical studies of a product candidate may not be
predictive of success in subsequent clinical studies of that
candidate; Daré’s ability to retain its licensed rights to develop
and commercialize a product candidate; Daré’s ability to satisfy
the monetary obligations and other requirements in connection with
its exclusive, in-license agreements covering the critical patents
and related intellectual property related to its product
candidates; developments by Daré’s competitors that make its
product candidates less competitive or obsolete; Daré’s dependence
on third parties to conduct clinical trials and manufacture
clinical trial material; Daré’s ability to adequately protect or
enforce its, or its licensor’s, intellectual property rights; the
lack of patent protection for the active ingredients in certain of
Daré’s product candidates which could expose its products to
competition from other formulations using the same active
ingredients; the risk of failure associated with product candidates
in preclinical stages of development that may lead investors to
assign them little to no value and make these assets difficult to
fund; and disputes or other developments concerning Daré’s
intellectual property rights. Daré’s forward-looking statements are
based upon its current expectations and involve assumptions that
may never materialize or may prove to be incorrect. All
forward-looking statements are expressly qualified in their
entirety by these cautionary statements. For a detailed description
of Daré’s risks and uncertainties, you are encouraged to review its
documents filed with the SEC including Daré’s recent filings on
Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place
undue reliance on forward-looking statements, which speak only as
of the date on which they were made. Daré undertakes no obligation
to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as required by law.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:Lee
Roth Burns McClellan lroth@burnsmc.com 212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.:Jake
Robison Canale Communications jake@canalecomm.com
619.849.5383
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024